Walder Wyss advises BiomedPartners AG as Lead Investor in connection with TOLREMO’s CHF 9 million Series A Financing Round. TOLREMO was founded as an ETH spin-off…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
